An Open-Label, Phase I Dose Escalation Trial of MVA-BN-PRO in Men With Androgen-Insensitive Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2013
At a glance
- Drugs MVA-BN-PRO (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 13 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Bavarian Nordic media release. Results were also briefly summarised in the media release.
- 25 Jan 2012 Additional lead trial investigator (Bandman O) identified as reported by ClinicalTrials.gov.
- 27 Jun 2011 Planned end date changed from 1 Aug 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.